南新制药(688189) - 2020 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 325,616,521.18, reflecting a growth of 39.89% compared to the same period last year[6] - Net profit attributable to shareholders increased by 28.22% to CNY 26,378,655.96 year-over-year[6] - Total operating revenue for Q1 2020 reached ¥325,616,521.18, a 39.8% increase from ¥232,767,051.46 in Q1 2019[28] - Net profit for Q1 2020 was ¥28,512,421.77, representing a 38.7% increase compared to ¥20,573,320.06 in Q1 2019[29] - Total profit for Q1 2020 was ¥34,505,344.74, up 34.2% from ¥25,716,650.08 in Q1 2019[28] - Total comprehensive income for Q1 2020 was CNY 15,096,347.65, compared to CNY 9,551,745.58 in Q1 2019, representing a year-over-year increase of approximately 58.5%[33] Assets and Liabilities - Total assets increased by 143.22% to CNY 1,991,252,498.15 compared to the end of the previous year[6] - Total liabilities amounted to ¥470,191,618.25, up from ¥461,451,171.79, indicating a rise in overall debt levels[23] - Current liabilities rose to ¥349,873,229.51 compared to ¥340,705,187.62, showing an increase in short-term financial obligations[22] - The company's total liabilities and equity reached ¥1,767,260,528.57, up from ¥590,376,152.39, showcasing overall financial growth[26] Shareholder Information - The total number of shareholders reached 19,261 by the end of the reporting period[10] - The top ten shareholders held a combined 85.00% of the company's shares, with the largest shareholder owning 28.57%[10] Cash Flow - The net cash flow from operating activities decreased by 90.35% to CNY 7,360,155.36 compared to the previous year[6] - Cash inflow from operating activities for Q1 2020 was CNY 336,025,280.86, compared to CNY 278,356,781.09 in Q1 2019, reflecting a growth of approximately 20.7%[34] - Cash outflow from operating activities totaled CNY 328,665,125.50 in Q1 2020, compared to CNY 202,118,473.59 in Q1 2019, which is an increase of about 62.5%[34] - Cash flow from financing activities showed a significant increase to CNY 1,143,043,149.56, compared to a negative cash flow of CNY 21,099,449.26 in the same period last year, reflecting successful fundraising efforts[12] Research and Development - Research and development expenses accounted for 6.75% of operating revenue, up from 5.98% in the previous year[6] - Research and development expenses increased by 57.96% to CNY 21,984,332.59 in Q1 2020, compared to CNY 13,917,686.16 in Q1 2019, indicating a focus on innovative drug development[12] - The company signed a technology development contract for the project "Oseltamivir Phosphate Dry Suspension" with a total R&D cost of CNY 30 million[13][15] - The company is advancing several new drug projects, including "Mefenamic Acid" for diabetic nephropathy and "Paxlovid" for influenza, with various stages of clinical trials ongoing[19] Earnings Per Share - Basic and diluted earnings per share were CNY 0.1884, down 3.83% from CNY 0.1959 in the previous year[6] - Basic earnings per share for Q1 2020 were ¥0.1884, slightly down from ¥0.1959 in Q1 2019[29]